Search - tctmd.com

Displaying 21 - 40 of 48

Sort: Relevancy | Date

Presentation TCT 2022

Case 2: COVID Patient With Clot in Transit

Presenter: Matthew Finn

September 18, 2022

Presentation TVT 2022

Approach to TAVR in Setting of a Complicated Left Atrial Thrombus in Transit

Presenter: Rimmy Garg

June 08, 2022

Presentation Fellows 2022

My Experience as a Complex Coronary Operator

Presenter: Mohsin Chowdhury

May 07, 2022

Presentation Fellows 2022

My Experience as a Structural Operator

Presenter: Jay Patel

May 07, 2022

Presentation Fellows 2022

My Experience as a Complex Coronary Operator

Presenter: Conrad Jablonski

May 07, 2022

Presentation TCT 2020

TRANSIT: Treatment of Failed TAVR With TAVR

Presenter: Luca Testa

October 17, 2020

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

Presentation TCT 2019

Transitioning to Monotherapy in Patients After PCI

Presenter: Pascal Vranckx

September 26, 2019

Presentation CDM 2017

Transitiong From a CAD to Peripheral Vascular Disease Practice

Presenter: Terry R. Bowers

October 05, 2017

Presentation TVT 2017

Snapshot #1: Making the Transition to Awake TAVR - A Guide for Lower-Volume Centers

Presenter: Axel Linke, Bernard Prendergast, Kendra J. Grubb

June 16, 2017

Presentation ISET 2017

Clot in Transit: Diagnosis and Treatment

Presenter: John Moriarty

February 04, 2017

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Early Insights from Industry

Presenter: Charles J. Davidson, Nicole Ibrahim, Dan Mans

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation TVT 2016

TVT 1146: First-in-Man Experience of Using the Aegis Surgical Transit (TM) System for Suprasternal TAVR Using a Self-Expanding Valve

Presenter: John P Vavalle, MD, MHS, FACC

June 17, 2016

Presentation TCT 2015

Cangrelor IV: Transitioning to Oral ADP Antagonists

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation

Optimal Catchment Area, Primary PCI Center Volume Revisited: A Single-Center Experience in Transition From High-Volume to “Mega Center” for STEMI

Presenter: Mikkel Malby Schoos

December 28, 2014

Presentation TCT 2014

Bendavia to Prevent Mitochondrial Transition Pore Opening

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Amir Lerman, C. Michael Gibson

September 16, 2014

Advertisement

Case 2: COVID Patient With Clot in Transit

Approach to TAVR in Setting of a Complicated Left Atrial Thrombus in Transit

My Experience as a Complex Coronary Operator

My Experience as a Structural Operator

My Experience as a Complex Coronary Operator

TRANSIT: Treatment of Failed TAVR With TAVR

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Transitioning to Monotherapy in Patients After PCI

Transitiong From a CAD to Peripheral Vascular Disease Practice

Snapshot #1: Making the Transition to Awake TAVR - A Guide for Lower-Volume Centers

Clot in Transit: Diagnosis and Treatment

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

TMVR Clinical Trial Design: Early Insights from Industry

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

FDA Perspectives

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

TVT 1146: First-in-Man Experience of Using the Aegis Surgical Transit (TM) System for Suprasternal TAVR Using a Self-Expanding Valve

Cangrelor IV: Transitioning to Oral ADP Antagonists

Optimal Catchment Area, Primary PCI Center Volume Revisited: A Single-Center Experience in Transition From High-Volume to “Mega Center” for STEMI

Bendavia to Prevent Mitochondrial Transition Pore Opening

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content